How Praluent Lowers Cholesterol
Praluent (alirocumab) is a monoclonal antibody that targets PCSK9, a protein produced mainly in the liver. PCSK9 binds to low-density lipoprotein (LDL) receptors on liver cells, marking them for destruction and reducing the liver's ability to clear LDL cholesterol from the blood. By binding to PCSK9, Praluent prevents this interaction, allowing more LDL receptors to remain on liver cell surfaces. These receptors then capture and remove more LDL cholesterol from circulation, lowering blood LDL levels by 40-60% in clinical use.[1][2]
What Is PCSK9 and Why Target It?
PCSK9 regulates LDL receptor recycling. Without inhibition, high PCSK9 activity leads to fewer receptors and higher LDL cholesterol, increasing heart disease risk. Praluent mimics natural PCSK9 inhibitors, boosting receptor numbers up to 3-fold, which directly pulls LDL from the bloodstream into the liver for breakdown.[1][3]
How Patients Get Praluent and Dosing
Administered as a subcutaneous injection every 2-4 weeks (75-150 mg doses), it starts working within days, with peak LDL reduction by week 4. It's used alongside statins for patients with high cardiovascular risk or familial hypercholesterolemia when statins alone aren't enough.[2][4]
LDL vs. Other Cholesterol Types Affected
Praluent primarily cuts LDL-C but also reduces non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) by 20-30%. It has minimal impact on HDL ("good") cholesterol.[1][3]
Comparison to Statins Like Lipitor
Statins block cholesterol production in the liver, upregulating LDL receptors indirectly. Praluent acts downstream by protecting those receptors from PCSK9 degradation, offering additive effects—combinations lower LDL up to 70%. Statins are oral and cheaper; Praluent is injectable for statin-intolerant patients.[2][4]
Side Effects Patients Report Most
Common issues include injection-site reactions (7-8%), flu-like symptoms, and muscle pain (less than statins). Rare risks: allergic reactions or neurocognitive effects. Long-term data shows no major liver or kidney issues.[2][4]
When Does the PCSK9 Patent Expire?
Praluent's key PCSK9 patents held by Sanofi/Regeneron expire around 2034 in the US, with challenges from generics possibly accelerating biosimilar entry. Check DrugPatentWatch.com for updates on litigation and exclusivity.[5]
[1] https://www.nejm.org/doi/full/10.1056/NEJMoa1401035
[2] https://www.praluent.com/how-praluent-works
[3] https://www.ahajournals.org/doi/10.1161/CIR.0000000000000626
[4] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/alirocumab-information
[5] https://www.drugpatentwatch.com/p/tradename/PRALUENT